启迪药业集团股份公司第十届董事会第七次会议决议公告

Core Viewpoint - The company has undergone a change in control, with new leadership appointments and committee restructuring following the acquisition of shares by Hunan Sailoxian Management Consulting Partnership [19][20][21]. Group 1: Board Resolutions - The company held its seventh meeting of the tenth board on September 23, 2025, where key resolutions were passed [13][21]. - Jiang Xin was elected as the chairman of the tenth board of directors [13][21]. - Jiang Xin and Zhou Yanqi were appointed as members of the board's strategic committee, with Jiang Xin serving as the chairman of this committee [3][4]. - Ni Xiaoqiao was appointed as a member of the board's audit committee [5][6]. - Jiang Xin was appointed as the company's president, and Qiao Xuefeng was appointed as the vice president [7][9]. Group 2: Change of Control - On July 15, 2025, Hunan Sailoxian successfully auctioned 58,606,962 shares from the original controlling shareholder, accounting for 24.47% of the company's total share capital [20]. - The transfer of ownership was completed on August 11, 2025, following the judicial auction [20]. - The change in control was finalized on September 22, 2025, with the election of Jiang Xin and Zhou Yanqi as non-independent directors [21].